These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31544866)

  • 1. Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H.
    Fülöp T; Mészáros T; Kozma GT; Szebeni J; Józsi M
    Antibodies (Basel); 2018 Mar; 7(1):. PubMed ID: 31544866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals.
    Szebeni J
    Mol Immunol; 2014 Oct; 61(2):163-73. PubMed ID: 25124145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.
    Neun BW; Barenholz Y; Szebeni J; Dobrovolskaia MA
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30002298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro.
    Mészáros T; Csincsi ÁI; Uzonyi B; Hebecker M; Fülöp TG; Erdei A; Szebeni J; Józsi M
    Nanomedicine; 2016 May; 12(4):1023-1031. PubMed ID: 26733258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
    Szebeni J
    Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Acute Anaphylactoid Reactogenicity of Nanoparticle-Containing Medicines and Vaccines Using the Porcine CARPA Model.
    Szebeni J
    Methods Mol Biol; 2024; 2789():229-243. PubMed ID: 38507008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
    Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
    J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information.
    Fülöp T; Nemes R; Mészáros T; Urbanics R; Kok RJ; Jackman JA; Cho NJ; Storm G; Szebeni J
    J Control Release; 2018 Jan; 270():268-274. PubMed ID: 29203414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
    Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
    Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions.
    Szebeni J; Bawa R
    Biomedicines; 2020 Apr; 8(4):. PubMed ID: 32276476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody.
    Szebeni J; Fontana JL; Wassef NM; Mongan PD; Morse DS; Dobbins DE; Stahl GL; Bünger R; Alving CR
    Circulation; 1999 May; 99(17):2302-9. PubMed ID: 10226097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
    Szebeni J; Muggia F; Gabizon A; Barenholz Y
    Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
    Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated liposomes: immunological responses.
    Mohamed M; Abu Lila AS; Shimizu T; Alaaeldin E; Hussein A; Sarhan HA; Szebeni J; Ishida T
    Sci Technol Adv Mater; 2019; 20(1):710-724. PubMed ID: 31275462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.
    Szebeni J; Storm G
    Biochem Biophys Res Commun; 2015 Dec; 468(3):490-7. PubMed ID: 26182876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
    Szebeni J
    Toxicology; 2005 Dec; 216(2-3):106-21. PubMed ID: 16140450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of KU812 cells for assessing complement activation related effects by nano(bio)materials.
    David CAW; de la Fonteyne-Blankestijn LJJ; Vermeulen JP; Plant-Hately AJ; Vandebriel RJ; Liptrott NJ
    Biomed Pharmacother; 2023 Jul; 163():114841. PubMed ID: 37167727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.
    Dézsi L; Mészáros T; Őrfi E; Fülöp TG; Hennies M; Rosivall L; Hamar P; Szebeni J; Szénási G
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31505853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.
    Szebeni J; Alving CR; Savay S; Barenholz Y; Priev A; Danino D; Talmon Y
    Int Immunopharmacol; 2001 Apr; 1(4):721-35. PubMed ID: 11357884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice.
    Leinhase I; Rozanski M; Harhausen D; Thurman JM; Schmidt OI; Hossini AM; Taha ME; Rittirsch D; Ward PA; Holers VM; Ertel W; Stahel PF
    J Neuroinflammation; 2007 May; 4():13. PubMed ID: 17474994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.